To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: SARS-CoV-2 Infection, COVID-19, Maternal Immunization

In brief

Results will be submitted, however please note that data are not yet available for all serology outcome measures. This will be a Phase 2/3, randomized, placebo-controlled, observer-blind study evaluating the safety, tolerability, and immunogenicity of 30 µg of BNT162b2 or placebo administered in 2 doses, 21 days apart, in approximately 350 healthy pregnant women 18 years of age or older vaccinated at 24 to 34 weeks' gestation. Participants will be randomized 1:1 to receive BNT162b2 or placebo (saline).

Key facts

Study ID

NCT04754594

Run by

BioNTech SE

People needed

726

Starts

2021-02-16

Expected to finish

2022-07-15

Last updated by the study team

2024-12-06

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy women ≥18 years of age who are between 24 0/7 and 34 0/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications.
• Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• Healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study
• Documented negative HIV antibody test (Phase 2 only), syphilis test, and HBV surface antigen test during this pregnancy and prior to randomization
• Participant is willing to give informed consent for her infant to participate in the study
• Capable of giving signed informed consent

You may not qualify if…

• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.
• Participants with known or suspected immunodeficiency.
• Bleeding diathesis or condition associated with prolonged bleeding that would in the opinion of the investigator contraindicate intramuscular injection.
• Previous vaccination with any coronavirus vaccine.
• Receipt of medications intended to prevent COVID 19.
• Receipt of blood/plasma products or immunoglobulin, from 60 days before administration of study intervention, or planned receipt through delivery, with 1 exception, anti-D immunoglobulin (eg, RhoGAM), which can be given at any time.
• Current alcohol abuse or illicit drug use.
• Participants who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt through the postvaccination blood draw.
• Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.
• Previous participation in other studies involving study intervention containing LNPs.
• Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
• Participants whose unborn baby has been fathered by investigational site staff members directly involved in the conduct of the study or their family members, site staff members otherwise supervised by the investigator, or Pfizer employees directly involved in the conduct of the study.

Where it is running

• University of Alabama at Birmingham Women & Infant Center — Birmingham, Alabama, United States
• University of Alabama at Birmingham/Center for Women's Reproductive Health — Birmingham, Alabama, United States
• Velocity Clinical Research, Gulfport — Mobile, Alabama, United States
• Arrowhead Hospital — Glendale, Arizona, United States
• Abrazo West Campus Hospital — Goodyear, Arizona, United States
• St. Joseph Hospital — Phoenix, Arizona, United States
• MedPharmics, LLC — Phoenix, Arizona, United States
• Matrix Clinical Research. — Huntington Park, California, United States
• Matrix Clinical Research — Huntington Park, California, United States
• Chemidox Clinical Trials Inc. — Lancaster, California, United States
• East LA Doctors Hospital — Los Angeles, California, United States
• Matrix Clinical Research — Los Angeles, California, United States
• Axcess Medical Research — Loxahatchee Groves, Florida, United States
• Idaho Falls Pediatrics — Ammon, Idaho, United States
• Bingham Memorial Hospital — Blackfoot, Idaho, United States
• Idaho Falls Pediatrics — Idaho Falls, Idaho, United States
• Clinical Research Prime — Idaho Falls, Idaho, United States
• Eastern Idaho Regional Medical Center — Idaho Falls, Idaho, United States
• Mountain View Hospital — Idaho Falls, Idaho, United States
• Covenant Healthcare — Saginaw, Michigan, United States
• Saginaw Valley Medical Research Group, LLC — Saginaw, Michigan, United States
• Community Hospital of Anaconda — Anaconda, Montana, United States
• Boeson Research (BUT) — Butte, Montana, United States
• SCL St. James Healthcare Hospital — Butte, Montana, United States
• Children's of Alabama — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.